Development

Company-Sponsored Trials

Program
Indication
  • Phase 1
  • Phase 2
  • Phase 3
  • Approved
Phase
Program
Indication
  • Ph1
  • Ph2
  • Ph3
  • App.
Phase

Multiply relapsed aggressive B-cell non-Hodgkin lymphoma (NHL)

Ph3

PIX306: Aggressive NHL, 2nd line, combination with rituximab (post-approval study)

Ph1

PERSIST-1: Myelofibrosis, All platelet counts

Ph3

PERSIST-2: Myelofibrosis, Platelet counts ≤100,000/μL

Ph3

Relapsed AML

Ph2

Select Investigator-Sponsored Trials

Program
Indication
  • Phase 1
  • Phase 2
  • Phase 3
  • Approved
Phase
Program
Indication
  • Ph1
  • Ph2
  • Ph3
  • App.
Phase

Relapsed/refractory AML/MDS

Ph2

Ovarian cancer, 1st line maintenance

Ph3

Newly diagnosed glioblastoma without MGMT methylation

Ph2

Head and neck cancer

Ph2

1Confirmatory Phase 3 trial. PIXUVRI® has conditional approval in the E.U. The benefit of PIXUVRI® treatment has not been established in patients when used as fifth-line or greater chemotherapy in patients who are refractory to last therapy.

You Are Leaving CTI BioPharma

You have selected a link to a third-party website. This link is provided solely as a convenience to you and not as an endorsement by CTI BioPharma of such third-party website. CTI BioPharma is not responsible for and does not make any representations regarding the accuracy of materials on such third-party site.

Continue to the Requested Site
Return to CTI BioPharma

Hello! We are pleased to announce that Cell Therapeutics has changed its name to

Enter Site